Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Scheinberg

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Cancer Research|March 31, 2001
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591)A M Ballangrud, W H Yang, D E Charlton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 24, 1999
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemiaG Sgouros, A M Ballangrud, J G Jurcic, et al.
Science (New York, N.Y.)|November 17, 2001
Tumor therapy with targeted atomic nanogeneratorsM R McDevitt, D Ma, L T Lai, et al.
The New England Journal of Medicine|November 5, 1998
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxideS L Soignet, P Maslak, Z G Wang, et al.
Bone Marrow Transplantation|September 4, 2003
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemiasJ M Burke, P C Caron, E B Papadopoulos, et al.
Oncogene|June 9, 2016
VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumorsF Röhrig, S Vorlová, H Hoffmann, et al.
Leukemia|October 20, 2006
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphomaT Ise, S Nagata, R J Kreitman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaS L Soignet, S R Frankel, D Douer, et al.
Cancer Research|November 21, 2000
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancerM R McDevitt, E Barendswaard, D Ma, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Cancer Research|March 31, 2001
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591)A M Ballangrud, W H Yang, D E Charlton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 24, 1999
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemiaG Sgouros, A M Ballangrud, J G Jurcic, et al.
Science (New York, N.Y.)|November 17, 2001
Tumor therapy with targeted atomic nanogeneratorsM R McDevitt, D Ma, L T Lai, et al.
The New England Journal of Medicine|November 5, 1998
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxideS L Soignet, P Maslak, Z G Wang, et al.
Bone Marrow Transplantation|September 4, 2003
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemiasJ M Burke, P C Caron, E B Papadopoulos, et al.
Oncogene|June 9, 2016
VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumorsF Röhrig, S Vorlová, H Hoffmann, et al.
Leukemia|October 20, 2006
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphomaT Ise, S Nagata, R J Kreitman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaS L Soignet, S R Frankel, D Douer, et al.
Cancer Research|November 21, 2000
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancerM R McDevitt, E Barendswaard, D Ma, et al.
Pageof 13